IN8BIO, Inc.
INAB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001740279
No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding IN8BIO, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 26 | 1 | 26 | +1 |
| Shares | 7.74M | 57.1K | 7.63M | −59.5K (−0.8%) |
| Value | $6.77M | $48.3K | $2.06M | −$4.67M (−69.4%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (6)
Institutions that held IN8BIO, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 59,216 | $16.0K | 0.00% |
| Virtu Financial LLC | 52,807 | $14.0K | 0.00% |
| Jane Street Group, LLC | 29,223 | $7.89K | 0.00% |
| UBS Group AG | 26,270 | $7.09K | 0.00% |
| LPL Financial LLC | 12,350 | $3.33K | 0.00% |
| Barclays PLC | 102 | $28 | 0.00% |
Sold out (5)
Institutions that held IN8BIO, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Bridgeway Capital Management, LLC | 103,302 | $87.4K |
| Two Sigma Securities, LLC | 69,718 | $59.0K |
| Laird Norton Trust Company, LLC | 42,300 | $35.8K |
| Charles Schwab Investment Management Inc | 13,105 | $11.1K |
| Royal Bank of Canada | 215 | $0 |
Not filed for Q3 2024 yet (1)
Institutions that held IN8BIO, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 57,080 | $48.3K |